Additionally, the FDA has confirmed that this product is eligible for 180-days of generic drug exclusivity for Ipratropium Bromide HFA Inhalation Aerosol as we were the first ANDA applicant with ...

Overview: Nasal ipratropium is used to help reduce symptoms of a runny nose. It works by reducing the amount of liquid and mucus made in your nose. Common side effects can include dryness of the nose, ...

Ipratropium bromide 0.06% (42mcg/spray); aqueous soln. Ipratropium bromide, an anticholinergic (parasympatholytic) agent, has antisecretory properties which inhibit secretions from the serous and ...

Ipratropium bromide 0.5 mg/3 mL (0.017%), albuterol (as sulfate) 2.5 mg/3 mL (0.083%); soln for inh. Not for primary treatment of acute attack. Avoid excessive use. Discontinue if paradoxical ...

Global pharma major Lupin Limited (Lupin) announced the launch of ipratropium bromide nasal solution (nasal spray), 0.03% and 0.06%, in the United States. Ipratropium bromide nasal solution (nasal ...

RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" ...

Background: Studies have suggested an increased risk of cardiovascular morbidity and mortality associated with the use of ipratropium bromide. We sought to examine the association between ipratropium ...

As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare ...

The Food and Drug Administration has advised consumers not to use certain respiratory medications purchased after Sept. 8, 2009 and manufactured by Dey L.P., a subsidiary of Mylan Inc., because the ...

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's ...